NASDAQ$CARM
Carisma Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Carisma Therapeutics reported Q1 2025 a net loss of $9.3M, diluted EPS of $-0.22.
For Q1 2025, Carisma Therapeutics reported net loss was $9.3M, diluted EPS was $-0.22. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $9.3M.
- Diluted EPS $-0.22.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Carisma Therapeutics · Revenue · Quarterly
$3.7M
Revenue by segment
Carisma Therapeutics · $19.6M total across 1 segment · Q4 2024
- Collaboration Revenues$19.6M—100.0%
Forward guidance
Outlook emphasizes clinical milestones, liquidity runway, and cost discipline.
Tailwinds
- Pipeline readouts and partnership economics.
- Cash balance supports near-term development plans.
Headwinds
- Operating losses and trial risk until commercialization.
- Financing markets and competition affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2025
+0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+6.2%
Avg return
30 days after
54%
26 / 48 earnings
Positive
+32.8%
Q2 2016
Best reaction
-29.2%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +6.2% | +10.1% | -98.0% | |
| Q3 2025 | +2.4% | +27.8% | +22.6% | |
| Q2 2025 | -11.8% | -8.6% | +31.7% | |
| Q1 2025 | +3.1% | -1.4% | +153.1% | |
| Q4 2024 | +11.5% | +5.7% | -5.6% | |
| Q3 2024 | -9.0% | -10.4% | -28.0% | |
| Q2 2024 | +10.7% | +26.2% | +25.0% | |
| Q1 2024 | -4.5% | -5.8% | -30.3% | |
| Q4 2023 | -11.5% | -19.8% | -28.2% | |
| Q3 2023 | -19.5% | -11.1% | -15.4% | |
| Q2 2023 | +12.9% | +22.4% | -12.9% | |
| Q1 2023 | -12.3% | -17.7% | +4.1% | |
| Q4 2022 | +1.2% | -9.6% | +62.9% | |
| Q3 2022 | +0.5% | — | — | |
| Q2 2022 | -3.6% | — | — | |
| Q1 2022 | -1.3% | — | — | |
| Q4 2021 | -2.5% | — | — | |
| Q3 2021 | +3.4% | — | — | |
| Q2 2021 | -8.8% | — | — | |
| Q1 2021 | +5.4% | — | — | |
| Q4 2020 | +5.6% | — | — | |
| Q3 2020 | +3.9% | — | — | |
| Q2 2020 | +7.0% | — | — | |
| Q1 2020 | +1.6% | — | — | |
| Q4 2019 | -29.2% | — | — | |
| Q3 2019 | +0.9% | — | — | |
| Q2 2019 | +1.7% | — | — | |
| Q1 2019 | -2.9% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | -7.0% | — | — | |
| Q2 2018 | +2.1% | — | — | |
| Q1 2018 | +17.1% | — | — | |
| Q4 2017 | +19.0% | — | — | |
| Q3 2017 | +2.8% | — | — | |
| Q2 2017 | -12.4% | — | — | |
| Q1 2017 | -2.7% | — | — | |
| Q4 2016 | +13.7% | — | — | |
| Q3 2016 | -4.2% | — | — | |
| Q2 2016 | +32.8% | — | — | |
| Q1 2016 | +6.1% | — | — | |
| Q4 2015 | -8.6% | — | — | |
| Q3 2015 | -0.7% | — | — | |
| Q2 2015 | +15.2% | — | — | |
| Q1 2015 | +17.9% | — | — | |
| Q4 2014 | -2.4% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -3.9% | — | — | |
| Q1 2014 | +1.1% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro